Added to YB: 2025-08-14
Pitch date: 2025-08-12
NOVO-B.CO [neutral]
Novo Nordisk A/S
+0.19%
current return
Author Info
Quality Stocks helps you find valuable insights to become a better investor, discover quality companies, and find investment ideas. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 320.55
Price Target
750.00 (+134%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Stock of the Week - Novo Nordisk: A Fall from Grace Hiding Untapped Opportunities?
NOVO-B.CO (overview): New CEO facing increased competition (Eli Lilly) & US price pressure. Q2 strong but FY25 guidance cut to 8-14%. Stock near pre-GLP-1 levels offers good risk/reward despite margin squeeze risk. Still ~10% growth, strong FCF, large market share. Buying zones: 310DKK, 220DKK, 160DKK.
Read full article (2 min)